31 results
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... 100 cells/mm3 g/mL ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Treatment of Necrotizing Infections of the Skin, Fascia, and Muscle
 • Mixed infections
 • Streptococcus
IDSA Treatment of ... fasciitis #Skin #IDSA ... #Treatment #management ... #antibiotics #pharmacology
Direct-acting oral anticoagulants (DOACs) for VTE treatment and prevention - Comparison Table

#DOAC #Anticoagulants #Anticoagulation #VTE #Management
DOACs) for VTE treatment ... and prevention ... - Comparison Table ... VTE #Management #Pharmacology ... #Comparison #Table
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
IDSA Recommendations ... Trypanosomiasis #IDSA ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... if MIC<0.12 ug/ml ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... HumanPapillomavirus #IDSA ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis - IDSA 
Staphylococci, oxacillin susceptible
Staphylococci, oxacillin
Antimicrobial Treatment ... Osteomyelitis - IDSA ... Parenteral #IV #Antibiotics ... #pharmacology # ... idsa
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
IDSA Recommendations ... for Preventing ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... suspension 4–6 mL ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Outpatient Treatment ... fluoroquinolone #IDSA ... Acquired #Pneumonia #Antibiotics ... #Treatment #Regimen ... Management #Guidelines #pharmacology